PDSB PDS Biotechnology Corporation

2.82
+0.32  (+13%)
Previous Close 2.5
Open 2.65
Price To Book 1.04
Market Cap 16,296,357
Shares 5,778,850
Volume 50,838
Short Ratio
Av. Daily Volume 112,529
Stock charts supplied by TradingView

NewsSee all news

  1. PDS Biotechnology to Present at the 12th Annual LD Micro Main Event

    PRINCETON, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical stage immuno-oncology company with a broad pipeline of novel products based on the company's proprietary

  2. PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019

    PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company's proprietary Versamune®

  3. PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update

    PRINCETON, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ("PDS Biotechnology") (NASDAQ:PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating

  4. PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting

    PRINCETON, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the company's proprietary Versamune®

  5. PDS Biotechnology Corp. Announces Clinical Collaboration with Merck

    BERKELEY HEIGHTS, N.J., Oct. 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ("PDS Biotechnology") (NASDAQ:PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial will not be initiated - noted October 1, 2019.
PDS0101
Cervical intraepithelial neoplasia (CIN)
Phase 2 trial planned for 1Q 2020 with interim data due 2Q 2021. Phase 1 trial data to be presented at ASH December 8, 2019 6pm ET.
PDS0101
Head and neck cancer / human papillomavirus-16 (HPV16) infection
Phase 2a trial to commence 1Q 2020.
PDS0101 and chemoradiation
Cervical cancer

Latest News

  1. PDS Biotechnology to Present at the 12th Annual LD Micro Main Event

    PRINCETON, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical stage immuno-oncology company with a broad pipeline of novel products based on the company's proprietary

  2. PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019

    PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company's proprietary Versamune®

  3. PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update

    PRINCETON, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ("PDS Biotechnology") (NASDAQ:PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating

  4. PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting

    PRINCETON, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the company's proprietary Versamune®

  5. PDS Biotechnology Corp. Announces Clinical Collaboration with Merck

    BERKELEY HEIGHTS, N.J., Oct. 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ("PDS Biotechnology") (NASDAQ:PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional

  6. PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data

    BERKELEY HEIGHTS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ("PDS Biotechnology") (NASDAQ:PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional

  7. PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial

    60% of evaluable patients demonstrated a clinical response             Clinical activity observed at all dose levels Data support previously reported in-vivo induction of active HPV-specific (granzyme